Vivaldi Biosciences, a clinical-stage biotechnology company developing advanced vaccines for seasonal and pandemic influenza, recently announced the publication of Phase 1 clinical trial results for its deltaFLU vaccine for protection against influenza H5N1, a strain with pandemic potential. The data published in the journal Vaccine show that Vivaldi’s deltaFLU H5N1 vaccine induced a superior antibody response with a single intranasal dose.
The Phase 1 clinical trial demonstrated that 75% of the study volunteers achieved seroconversion (a 4-fold or greater increase in serum hemagglutination inhibition assay [HAI] H5N1 antibody levels) after one intranasal dose of the deltaFLU H5N1 vaccine. After two doses of deltaFLU, 92% of the volunteers achieved a 4-fold or greater increase in HAI antibody levels.
The results of the Phase 1 study of deltaFLU H5N1 compare favorably with manufacturers’ data for the two influenza H5N1 vaccines licensed by the US Food & Drug Administration (FDA). The licensed vaccines are administered by intramuscular injection in a two-dose regimen. In reported clinical studies of the licensed vaccines, neither vaccine achieved 75% seroconversion with the first dose.
Vivaldi’s high-efficiency, high-yield Vero cell production system can make deltaFLU vaccines available for distribution within 7 weeks of the declaration of an influenza pandemic. The vast majority of vaccines for seasonal and pandemic influenza are produced in chicken eggs. Traditional egg-based production takes up to 6 months, and may induce antigenic changes that reduce vaccine efficacy. The emergence of an avian influenza strain with pandemic potential could jeopardize egg-based production.
- Los Angeles: Health officials issue measles advisory
- Staph aureus found on 40 percent of cell phones at one university: Study
- Methanol poisoning cluster in Malaysia
- Hepatitis A: Martin County, FL officials urge vaccination
- Nipah: 12 bats test positive for the virus
- Texas: Anthrax confirmed in Uvalde County
- Ebola updates for DRC and Uganda, ‘Ebola is fake’ challenge
- Norovirus prompts recall of frozen berries sold at Walmart and Save-A-Lot